Published in final edited form as:

J Matern Fetal Neonatal Med. 2014 January ; 27(2): 132–144. doi:10.3109/14767058.2013.806905.

Plasma Concentrations of Angiogenic/Anti-Angiogenic Factors Have Prognostic Value in Women Presenting With Suspected Preeclampsia to the Obstetrical Triage Area: A Prospective Study

Tinnakorn Chaiworapongsa, MD^{1,2}, Roberto Romero, MD, D. Med. Sci.¹, Steven J Korzeniewski, PhD^{1,2}, Josef M Cortez, MD³, Athina Pappas, MD³, Adi L Tarca, PhD^{1,4}, Piya Chaemsaitong, MD^{1,2}, Zhong Dong, PhD¹, Lami Yeo, MD^{1,2}, and Sonia S Hassan, MD^{1,2}

¹Perinatology Research Branch, NICHD/NIH/DHHS, Bethesda, Maryland, USA

²Department of Obstetrics/Gynecology, Wayne State University, Detroit, Michigan, USA

³Department of Pediatrics, Wayne State University, Detroit, Michigan, USA

⁴Department of Computer Science, Wayne State University, Detroit, Michigan, USA

Abstract

Objective—To prospectively determine the prognostic value of maternal plasma concentrations of placental growth factor (PIGF), soluble endoglin (sEng) and soluble vascular endothelial growth factor receptors-1 and -2 (sVEGFR-1 and -2) in identifying patients with suspected preeclampsia (PE) who require preterm delivery (PTD) or develop adverse outcomes.

Study design—This prospective cohort study included 85 consecutive patients who presented to the obstetrical triage area at 20–36 weeks with a diagnosis of ‘rule out PE’. Patients were classified as: 1) those who remained stable until term (n=37); and 2) those who developed severe PE and required PTD (n=48). Plasma concentrations of PIGF, sEng and sVEGFR-1 and -2 were determined by ELISA.

Results—Patients with PIGF/sVEGFR-1 ≥ 0.05 multiples of the median (MoM) or PIGF/sEng ≥ 0.07 MoM were more likely to deliver preterm due to PE [adjusted odd ratio (aOR) 7.4 and 8.8], and to develop maternal (aOR 3.7 and 2.4) or neonatal complications (aOR 10.0 and 10.1). Among patients who presented <34 weeks of gestation, PIGF/sVEGFR-1 ≥ 0.035 MoM or PIGF/sEng ≥ 0.05 MoM had a sensitivity of 89% (16/18), specificity of 96% (24/25) and likelihood ratio for a positive test of 22 to identify patients who delivered within two weeks. The addition of the PIGF/sVEGFR-1 ratio to standard clinical tests improved the sensitivity at a fixed false-positive rate of 3% (p=0.004) for the identification of patients who were delivered due to PE within two weeks. Among patients who had a plasma concentration of PIGF/sVEGFR-1 ratio ≥ 0.035 MoM,

Address correspondence to: Tinnakorn Chaiworapongsa, MD and Roberto Romero, MD, Perinatology Research Branch, NICHD, NIH, DHHS, Wayne State University/Hutzel Women’s Hospital, 3990 John R, Box 4, Detroit, MI 48201, USA, Telephone (313) 993-2700, Fax: (313) 993-2694, tchaiwor@med.wayne.edu & romeror@mail.nih.gov.

Presented at the 58th Annual Meeting of the Society for Gynecologic Investigation, March 21–24, 2012, San Diego, CA

Declaration of Interest: The authors report no declaration of interest.

0.036–0.34 MoM and 0.35 MoM, the rates of PTD < 34 weeks were 94%, 27% and 7%, respectively.

Conclusions—The determination of angiogenic/anti-angiogenic factors has prognostic value in patients presenting to the obstetrical triage area with suspected preeclampsia for the identification of those requiring preterm delivery and at risk for adverse maternal/neonatal outcomes.

Keywords

maternal outcome; neonatal outcome; placental growth factor; soluble endoglin; soluble vascular endothelial growth factor receptor-1; pregnancy

INTRODUCTION

Preeclampsia (PE), one of the ‘great obstetrical syndromes’ [1–4], is characterized by systemic intravascular inflammation [5–7], endothelial cell dysfunction [8–11], excessive thrombin generation [12–18], an anti-angiogenic state [19–40] and is often associated with multiple organ involvement [1,41–60]. However, PE is fundamentally a placental disease [37,61–63] which manifests itself, in most cases, by involvement of the vascular (i.e. hypertension) and the renal systems (i.e. proteinuria). The diagnosis of PE typically requires the presence of hypertension and proteinuria [64]. Sometimes, patients who are subsequently are diagnosed with PE present initially with either hypertension [65–68] or proteinuria [69–73], and may have some signs or symptoms indicating yet, they do not meet the full diagnostic criteria for PE [74]. Indeed, even in some cases of HELLP syndrome, patients present without hypertension and proteinuria, and only develop these two abnormalities if pregnancy is allowed to continue [43,75]. In addition, when PE involves organs other than the vascular system and the kidney, it becomes the “great imitator” [76]. Such cases are frequently misdiagnosed and initially thought to have disorders unrelated to pregnancy. Hence, variability in clinical presentation presents a management challenge.

While approximately 1 in 10 pregnant women exhibit some signs and/or symptoms associated with PE, only 20%–25% of these patients will eventually be diagnosed as having the disease [77–79]. Women with signs and/or symptoms associated with PE (i.e. elevated blood pressure, headache, abdominal pain, edema, etc.) are frequently referred to an obstetrical triage area for assessment of multiple maternal organ systems and fetal involvement [80,81]. The standard work-up includes blood pressure determination, urine analysis for protein, a platelet count, determination of liver enzymes in peripheral blood, and a blood smear to detect schistocytes [64,79]. The prognostic performance of these tests in determining which patients will develop PE, require PTD, or have maternal and/or neonatal morbidity is poor [82–97]. Consequently, many patients with signs and/or symptoms associated with PE are hospitalized for observation. Those diagnosed with PE in preterm gestation often undergo long-term hospitalization or frequent monitoring as outpatients [98,99]. Thus, the lack of adequate biomarkers to predict disease progression and adverse outcomes in patients with suspected PE [82,84,100] results in substantial financial burden to the health care system (i.e. frequent visits, hospitalizations, intensive laboratory surveillance, serial ultrasound examination and antepartum testing) [101–105].

To address the need for biomarkers with high predictive value, we previously reported the results of a retrospective study which indicated that plasma concentrations of angiogenic/anti-angiogenic factors [placental growth factor (PlGF), soluble vascular endothelial growth factor receptors (sVEGFR-1), soluble endoglin (sEng)] have prognostic value in patients with “suspected PE” at preterm gestations who present to the obstetrical triage area [106]. We found that, based on the results of these analytes, it is possible to stratify patients into those at high, moderate and low risk of requiring PTD within 2 weeks [106].

The purpose of this study was to determine whether the results of the retrospective study could be replicated prospectively. Namely, to examine whether maternal plasma concentrations of angiogenic/anti-angiogenic factors have prognostic value in identifying patients presenting to the obstetrical triage area with the diagnosis ‘rule out PE’ and at risk for PTD due to PE or develop other complications within two weeks of presentation.

MATERIALS AND METHODS

Study design

This prospective cohort study included singleton pregnancies who presented to the obstetrical triage unit of Hutzel Women’s Hospital, Detroit, MI, for the diagnosis of “suspected PE” from July 2010 to March 2011. Inclusion criteria were: 1) singleton pregnancy; 2) no known major fetal anomaly; 3) gestational age 20–36 6/7 weeks; and 4) signs/symptoms of preeclampsia (elevated blood pressure, proteinuria, headache, blurred vision, epigastric or right upper quadrant pain and edema). All participants provided written informed consent and donated a blood sample for research purposes.

Based on our prior study [106], we estimated that approximately 40% of patients presenting with suspected preeclampsia prior to 37 weeks of gestation would have an abnormal biomarker ratio using thresholds selected based on ROC curve analysis. Accordingly, we estimated that to have 80% power to detect a 2-fold difference in the rate of preterm delivery due to severe PE (between patients with abnormal biomarker ratio compared to those with normal biomarker ratio) with a 5% limit on Type I error probability, 85 patients would be required. Considering patients to be excluded for loss to follow up (10%), we aimed to enroll 93 patients into this study.

Demographic data, medical, surgical and obstetrical history were recorded. Delivery outcomes were reviewed and used to classify patients into two groups: patients who remained stable until delivery at 37 weeks (Group I) and patients who developed severe PE requiring PTD (Group II). Maternal and neonatal complications within two weeks after presentation to the triage area were recorded as well. The collection and use of samples for research purposes was conducted under protocols approved by the Institutional Review Boards of Wayne State University and the *Eunice Kennedy Shriver* National Institute of Child Health and Human Development, National Institutes of Health, Department of Health and Human Services (NICHD/NIH/DHHS).

Clinical definitions

PE was defined as the new onset of hypertension and proteinuria that developed after 20 weeks of gestation. Hypertension was defined as systolic ≥ 140 or diastolic blood pressure ≥ 90 mm Hg, measured on two occasions, 4 hours to 1 week apart. Proteinuria was defined as a urine protein of ≥ 300 mg in a 24-h urine collection, or two random urine specimens obtained 4 hours to 1 week apart containing $\geq 1+$ by dipstick [64].

“Maternal morbidity” was considered to be present if one or more of the following complications was observed: 1) eclampsia; 2) HELLP syndrome; 3) pulmonary edema; 4) oliguria (<400 mL/day); 5) renal insufficiency (creatinine > 1.2 mg/dL); 6) abruption placentae (defined as clinical vaginal bleeding and uterine tenderness with or without placental pathologic findings); 7) elevated liver enzymes or thrombocytopenia; 8) antepartum admission to the maternal intensive care unit (MICU); or 9) fetal death. “Adverse neonatal outcome” was defined as one or more of the following complications: 1) respiratory distress syndrome [107,108]; 2) intraventricular hemorrhage [109]; 3) bronchopulmonary dysplasia [110]; or 4) neonatal death.

Patients were managed by attending physicians blinded to the results of the analytes under study. The approach in our institution is that patients with mild PE diagnosed prior to 37 weeks of gestation are managed expectantly, - with weekly platelet counts and liver function tests in addition to non-stress tests. Patients diagnosed with severe PE are hospitalized to assess maternal/fetal conditions and the need for delivery. Individually, patients are managed at the discretion of the attending physician.

Sample collection and immunoassays

Venipuncture was performed and blood was collected into tubes containing EDTA. Samples were centrifuged and stored at -70°C . Maternal plasma concentrations of PIGF, sVEGFR-1, sEng and sVEGFR-2 were determined by sensitive and specific immunoassays (R&D Systems, Minneapolis, MN) as previously described [106]. The inter- and intra-assay coefficients of variation (CV) obtained were as follows: PIGF, 6.02 and 4.8%, respectively; sEng, 2.3 and 4.6%, respectively; sVEGFR-1, 1.4 and 3.9%, respectively; and sVEGFR-2; 2 and 4%, respectively. The sensitivity of the assays were as follows: PIGF, 9.52 pg/ml; sVEGFR-1, 16.97 pg/ml; sEng, 0.08 ng/ml; and sVEGFR-2, 19.01 pg/ml.

Statistical analysis

Normality of data was assessed by inspection of histograms and the Kolmogorov-Smirnov test. Continuous variables were compared using the Mann-Whitney U or unpaired Student's t-tests depending upon the distribution of the data. Contingency tables and χ^2 tests were used to compare proportions. Methods used to construct maternal plasma angiogenic/anti-angiogenic factors and ratio concentration multiples of the median (MoM) have been previously reported [106]. Briefly, quantile regression was used to calculate the median concentration of a particular analyte and the ratio conditional upon gestational age in 180 participants in a longitudinal study at Hutzel Women's Hospital who had uncomplicated pregnancies and delivered at term. MoMs were calculated by dividing the observed analyte concentrations by the previously determined expected median ratio conditional on

gestational age. Dichotomization thresholds were selected in a prior study [106] based on inspection of receiver operating characteristic (ROC) curves.

Logistic regression was used to assess the magnitude of association between biomarkers and selected pregnancy outcomes. Multiple logistic regression models were constructed to account for potentially confounding factors selected based on clinical information (gestational age at presentation, average mean arterial blood pressure, chronic hypertension, combined parity and history of PE, and tobacco use). Potentially confounding factors were entered with respect to time-order into a full model. Model reduction was performed based on the plausibility of regression coefficients, association between independent and dependent variables, and the magnitude of change in the main effect parameter estimates; independent variables whose relationship with the dependent variable yielded a p -value >0.10 were excluded from the final models. Diagnostic performance metrics were calculated and correlated sample non-parametric statistical techniques were used to compare area under the ROC curves (AUC) [111]. Differences in sensitivity at a fixed false positive rate were tested using McNemar's tests, and exact p -values are reported.

Survival analysis and Cox proportional hazard models were utilized to examine the relationship between sampling-to-delivery interval and biomarker MoMs, adjusting for the above-mentioned potential confounders. Patients who delivered preterm due to causes other than PE had the interval between triage and delivery treated as a censored observation. Analysis was conducted with SPSS V.15 (SPSS Inc., Chicago, IL) and SAS version 9.3 (Carry, NC, U.S.A). A p value <0.05 was considered significant.

RESULTS

During the study period, 122 visits to the obstetrical triage unit for the diagnosis of "suspected PE" met the inclusion criteria. After exclusion of repeated visits ($n=19$), those who were lost to follow up ($n=8$), and those who declined to participate ($n=10$), 85 patients met the inclusion criteria. Among them, 37 remained stable until term (Group I) and 48 developed severe PE requiring PTD (Group II).

Demographic, clinical characteristics, pregnancy outcome and plasma concentrations of angiogenic/anti-angiogenic factors

Demographic/clinical characteristics, maternal morbidity and adverse neonatal outcomes are presented by group in Table I. Patients who developed severe PE and subsequently required a PTD had a higher mean systolic and diastolic blood pressure and a higher frequency of maternal morbidity and/or adverse neonatal outcomes than those who delivered at term (each $p<0.001$).

The median MoM plasma concentrations of angiogenic/anti-angiogenic factors differed significantly by patient groups (each $p<0.005$; Figure 1). A plasma concentration of PIGF/sVEGFR-1 of 0.05 MoM and that of PIGF/sEng 0.07 MoM had the highest likelihood ratio for a positive test (8.2). In contrast, a plasma concentration of PIGF 0.4 MoM had the lowest likelihood ratio for a negative test, 0.13 for the identification of patients who developed severe PE requiring a PTD (Table II).

Plasma concentrations of PIGF/sVEGFR-1 0.05 MoM and PIGF/sEng 0.07 MoM were significantly associated with indicated PTD due to PE, maternal morbidity, composite adverse neonatal outcome, and composite maternal morbidity and/or neonatal outcome after adjustment for potential confounders (Table III). The ratio of angiogenic/anti-angiogenic factors performed better than the mean arterial pressure or laboratory tests in identifying patients who required delivery within two weeks when the analysis was restricted to patients who presented prior to 34 weeks of gestation (Figure 2A; n=43) compared to analysis of the full cohort (Figure 2B; n=85). Therefore, subsequent analysis was restricted to patients who presented before 34 weeks of gestation.

Findings restricted to patients presenting prior to 34 weeks of gestation

Among patients who presented to the obstetrical triage area before 34 weeks, 18 (42%) delivered due to PE and 13 (30.2%) developed adverse maternal/neonatal outcomes within 2 weeks (Table IV). A ratio of PIGF/sVEGFR-1 0.035 MoM and a ratio of PIGF/sEng of 0.05 MoM achieved a sensitivity of 89% (16/18), a specificity of 96% (24/25) and a likelihood ratio for a positive and negative test of 22 and 0.12, respectively, in identifying patients who required delivery within 2 weeks (Table V). Table VI displays the magnitude of association between biomarker MoMs and selected outcomes. The ratios of PIGF/sVEGFR-1 0.035 MoM and PIGF/sEng 0.05 MoM were significantly associated with indicated PTD within 2 weeks (aOR 53 and 58 respectively) and composite maternal morbidity and/or adverse neonatal outcome within 2 weeks (aOR 19.5) after adjustment for potential confounders.

The biomarkers under study achieved a greater AUC (0.94–0.95) compared to combined standard clinical and laboratory tests (AUC 0.89) for the identification of patients who required PTD within 2 weeks. Table VII displays the sensitivity for the identification of patients who required delivery within 2 weeks or those who developed composite adverse maternal and/or neonatal outcomes within 2 weeks by pre-specified false-positive rate (3%, 5% and 10%) for biomarker MoMs, blood pressure and standard laboratory tests for PE. The addition of the PIGF/sVEGFR-1 ratio to standard tests significantly improved the sensitivity at a fixed false-positive rate of 3% ($p=0.004$) and marginally improved sensitivity at a fixed false-positive rate of 5% ($p=0.06$) for the identification of patients who would be delivered due to PE within two weeks (Figure 3). Therefore, angiogenic/anti-angiogenic factor MoMs outperformed the standard tests used in the triage area for the prediction of these adverse outcomes, given that they had a higher sensitivity than standard laboratory tests.

Time-to-event analysis confirmed that a low maternal PIGF/sVEGFR-1 ratio (0.035 MoM) or PIGF/sEng ratio (0.05 MoM) was associated with a shorter interval-to-delivery after adjusting for potential confounders - gestational age at presentation, average mean arterial blood pressure, chronic hypertension, combined parity and history of PE, and tobacco use [hazard ratio = 25 (95% CI 6.4–104.0) and 29.4 (95% CI 6.9–125.1); respectively; Figure 4].

Table VIII displays the disposition (hospitalization versus discharge home) of the patient after visiting the triage area, rate of PTD and adverse perinatal outcomes according to the previously proposed grading of severity criteria based on plasma MoM concentrations of the PIGF/sVEGFR-1 ratio and the PIGF/sEng ratio [106]. The cut-off values for patients at

high-risk were based on ROC curves for the identification of patients who delivered within 2 weeks and those for patients at low-risk were based on ROC curves for the identification of patients who remained stable until term [106]. Almost 40% of patients presenting prior to 34 weeks had analyte ratio MoM concentrations classified as Zone 3 (high-risk), while 35%–42% were characterized as low-risk (Zone 1) and 20–25% were considered moderate risk (Zone 2). Thirty-three (77%) patients who presented to the triage area with “suspected PE” at less than 34 weeks were hospitalized. Among them, one-third (11/33) were classified as Zone 1 (low risk). Nine of these eleven patients did not have hypertension in the severe range, and five complained of headache in the triage area. A single patient within Zone 1 (6.7%) delivered within 2 weeks and had an abnormal liver function test. This patient had chronic hypertension and was referred to the triage area at 31 4/7 weeks because of an elevated blood pressure (161/86 mmHg).

In contrast, among patients classified as high-risk (Zone 3) by either a PIGF/sVEGFR-1 ratio 0.035 MoM or a PIGF/sEng ratio 0.05 MoM, the rate of PTD before 34 weeks was 94% (16/17) and 100% (17/17) respectively; the rate of PTD within 2 weeks was 94% (16/17) for each ratio, and the rate of composite adverse maternal and/or neonatal outcome within 2 weeks of visiting the triage area was 70% (12/17) for each ratio (Table VIII).

DISCUSSION

Principal findings of the study

1) Patients who presented to the obstetrical triage area with “suspected PE” and subsequently required a PTD had a significantly lower mean plasma MoM concentration of angiogenic/anti-angiogenic ratio than those who remained stable until term; 2) low plasma concentrations of the PIGF/sVEGFR-1 ratio (< 0.05 MoM) or the PIGF/sEng ratio (< 0.07 MoM) were significantly associated with indicated PTD and composite maternal morbidity and/or adverse neonatal outcome in patients presenting at < 37 weeks of gestation; however, the ratio of angiogenic/anti-angiogenic factors performed better than standard laboratory tests in identifying patients who required delivery within two weeks when the analysis was restricted to patients who presented prior to 34 weeks of gestation; and 3) a PIGF/sVEGFR-1 ratio 0.035 MoM and a PIGF/sEng ratio 0.05 MoM were significantly associated with composite maternal morbidity and/or adverse neonatal outcome, and a shorter interval-to-delivery than those above these cutoffs among patients who presented < 34 weeks of gestation.

Meaning of the findings

The results of this study add further support to the concept that it is possible to classify patients presenting to the obstetrical triage area before 34 weeks of gestation with a suspected diagnosis of PE, based upon the results of PIGF, sVEGFR-1 and sEng [106,112]. We had previously proposed a three-tier classification of patients based on the results of these analytes and their ratios [106]. This classification yielded encouraging results, but needed replication. This is important because data-driven techniques for prediction generally perform well on the data set used for the development of a particular algorithm, but they generally underperform when applied to an independent sample. This is a key clinical

challenge because algorithms are developed for application to new patients, not in patients from whom the models were derived [113]. The current study was designed to test the value of the proposed classification system constructed based on retrospective data. This method classified patients into three groups: those at high, moderate and low risk for indicated PTD and/or adverse maternal or neonatal outcome.

The results of the current study independently confirm that our classification system has prognostic value in identifying patients at risk for PTD or adverse maternal/neonatal outcome. Among patients presenting prior to 34 weeks of gestation, those classified as “high risk” (Zone 3) had a 94% probability of PTD and 70% developed maternal and/or neonatal complications within 2 weeks. On the other hand, patients classified as “low risk” (Zone 1) were unlikely to deliver within 2 weeks (6.7%) or develop maternal and/or neonatal complications (6.7%). We propose that such patients can be discharged home after the managing physicians have performed a thorough evaluation and considered the likelihood of compliance with a regimen for monitoring and follow-up. For example, in this cohort, 9 of 11 patients who presented to the triage area before 34 weeks of gestation had maternal plasma concentrations of angiogenic/anti-angiogenic factors in Zone 1, and did not have blood pressure in the severe range or abnormal laboratory tests, but were hospitalized. All delivered more than 2 weeks (range 20–111 days) after the initial presentation.

The management of patients at intermediate risk (Zone 2) remains a challenge: 25%–27% delivered prior to 34 weeks of gestation, although few (9%–12%) developed maternal complications. Additional biomarkers will be required to improve the prognostic assessment of these patients. Alternatively, serial testing may prove to be informative.

Recently, a model to predict maternal complications in patients admitted with the diagnosis of PE has been proposed [114]. The current study had a different objective since we aimed to identify patients who required PTD and those who developed maternal and/or neonatal complications utilizing information in the triage area prior to admission.

Strengths and Limitations of the Study

The strengths of this study are its prospective nature and the independent replication of the previous findings [106]. Other than our first retrospective study of angiogenic/anti-angiogenic factors in the obstetrical triage area [106], three studies reported an association between maternal plasma angiogenic/anti-angiogenic factor concentrations in women who presented to the obstetrical triage area with suspected preeclampsia and adverse maternal and neonatal outcomes [112,115,116]. However, indicated preterm birth was included in the composite maternal and/or neonatal complications in these studies. We reported this outcome separately from other complications since this is an observational study and institutional management policies may influence this outcome (i.e. policy that required delivery of all patients with severe preeclampsia at 34 weeks of gestation). Moreover, we have gone beyond reporting an association between the results of biomarker determination and outcome by proposing an algorithm for follow up and management.

The limitations of this study include the lack of statistically significant differences in AUCs observed in this study when comparing the performance of standard clinical parameters and

the additional inclusion of angiogenic/anti-angiogenic factors. However, it is important to note that comparisons of the AUCs are insensitive measures of biomarker utility [117]. In other clinical fields (such as cardiovascular disease), the limitations of ROC curves as a tool for model evaluation have been recently highlighted, and the comparison of the AUC is considered an insensitive measure of improvement in model accuracy [117–119]. Second, this study utilized the conventional ELISA assay method rather than a rapid automated assay system whose results could be available for clinical decision-making in the obstetrical triage area. However, previous studies have demonstrated that measures obtained by rapid point-of-care and conventional ELISA assay systems are highly correlated [120–123]. Third, this is an observational study, and further investigation is required to determine whether implementation of management policies based upon the risk assessment would prove to be cost-effective and achieve the clinical goals.

Conclusion

Maternal plasma concentrations of angiogenic/anti-angiogenic factors have prognostic value for patients who present with suspected PE before 34 weeks of gestation. We propose that these biomarkers allow prospective stratification of patients whose illness will progress sufficiently to require a preterm delivery or develop adverse maternal and/or neonatal outcomes.

Acknowledgments

This research was supported, in part, by the Perinatology Research Branch, Division of Intramural Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Department of Health and Human Services (NICHD/NIH); and, in part, with Federal funds from NICHD, NIH under Contract No. HHSN275201300006C.

Reference List

1. Romero R, Lockwood C, Oyarzun E, Hobbins JC. Toxemia: new concepts in an old disease. *Semin Perinatol.* 1988; 12:302–23. [PubMed: 3065943]
2. Di Renzo GC. The great obstetrical syndromes. *J Matern Fetal Neonatal Med.* 2009; 22:633–5. [PubMed: 19736613]
3. Romero R. Prenatal medicine: the child is the father of the man. *Prenatal and Neonatal Medicine.* 1996; 1:8–11.
4. Brosens I, Pijnenborg R, Vercruysse L, Romero R. The “Great Obstetrical Syndromes” are associated with disorders of deep placentation. *Am J Obstet Gynecol.* 2011; 204:193–201. [PubMed: 21094932]
5. Gervasi MT, Chaiworapongsa T, Pacora P, Naccasha N, Yoon BH, Maymon E, Romero R. Phenotypic and metabolic characteristics of monocytes and granulocytes in preeclampsia. *Am J Obstet Gynecol.* 2001; 185:792–7. [PubMed: 11641653]
6. Redman CW, Sacks GP, Sargent IL. Preeclampsia: an excessive maternal inflammatory response to pregnancy. *Am J Obstet Gynecol.* 1999; 180:499–506. [PubMed: 9988826]
7. Redman CW, Sargent IL. Preeclampsia and the systemic inflammatory response. *Semin Nephrol.* 2004; 24:565–70. [PubMed: 15529291]
8. Roberts JM. Endothelial dysfunction in preeclampsia. *Semin Reprod Endocrinol.* 1998; 16:5–15. [PubMed: 9654603]
9. Roberts JM. Objective evidence of endothelial dysfunction in preeclampsia. *Am J Kidney Dis.* 1999; 33:992–7. [PubMed: 10328745]

10. Chaiworapongsa T, Romero R, Yoshimatsu J, Espinoza J, Kim YM, Park K, Kalache K, Edwin S, Bujold E, Gomez R. Soluble adhesion molecule profile in normal pregnancy and pre-eclampsia. *J Matern Fetal Neonatal Med.* 2002; 12:19–27. [PubMed: 12422905]
11. Petrozella L, Mahendroo M, Timmons B, Roberts S, McIntire D, Alexander JM. Endothelial microparticles and the antiangiogenic state in preeclampsia and the postpartum period. *Am J Obstet Gynecol.* 2012; 207:140–6. [PubMed: 22840727]
12. Cunningham FG, Pritchard JA. Hematologic considerations of pregnancy-induced hypertension. *Semin Perinatol.* 1978; 2:29–38. [PubMed: 734445]
13. Weenink GH, Treffers PE, Vijn P, Smorenberg-Schoorl ME, ten Cate JW. Antithrombin III levels in preeclampsia correlate with maternal and fetal morbidity. *Am J Obstet Gynecol.* 1984; 148:1092–7. [PubMed: 6711644]
14. Chaiworapongsa T, Yoshimatsu J, Espinoza J, Kim YM, Berman S, Edwin S, Yoon BH, Romero R. Evidence of in vivo generation of thrombin in patients with small-for-gestational-age fetuses and pre-eclampsia. *J Matern Fetal Neonatal Med.* 2002; 11:362–7. [PubMed: 12389649]
15. de Boer K, ten Cate JW, Sturk A, Borm JJ, Treffers PE. Enhanced thrombin generation in normal and hypertensive pregnancy. *Am J Obstet Gynecol.* 1989; 160:95–100. [PubMed: 2521425]
16. Erez O, Romero R, Kim SS, Kim JS, Kim YM, Wildman DE, Than NG, Mazaki-Tovi S, Gotsch F, Pineles B, et al. Over-expression of the thrombin receptor (PAR-1) in the placenta in preeclampsia: a mechanism for the intersection of coagulation and inflammation. *J Matern Fetal Neonatal Med.* 2008; 21:345–55. [PubMed: 18570113]
17. Dekker G. Prothrombotic mechanisms in preeclampsia. *Thromb Res.* 2005; 115 (Suppl 1):17–21. [PubMed: 15790144]
18. Erez O, Romero R, Hoppensteadt D, Than NG, Fareed J, Mazaki-Tovi S, Espinoza J, Chaiworapongsa T, Kim SS, Yoon BH, et al. Tissue factor and its natural inhibitor in pre-eclampsia and SGA. *J Matern Fetal Neonatal Med.* 2008; 21:855–69. [PubMed: 19065458]
19. Ahmed A, Whittle MJ, Khaliq A. Differential expression of placenta growth factor (PlGF) and vascular endothelial growth factor (VEGF) in abnormal placentation. *J Soc Gynecol Investig.* 1997; 4:246 A.
20. Zhou Y, McMaster M, Woo K, Janatpour M, Perry J, Karpanen T, Alitalo K, Damsky C, Fisher SJ. Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. *Am J Pathol.* 2002; 160:1405–23. [PubMed: 11943725]
21. Tsatsaris V, Goffin F, Munaut C, Brichant JF, Pignon MR, Noel A, Schaaps JP, Cabrol D, Frankenne F, Foidart JM. Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences. *J Clin Endocrinol Metab.* 2003; 88:5555–63. [PubMed: 14602804]
22. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. *J Clin Invest.* 2003; 111:649–58. [PubMed: 12618519]
23. Koga K, Osuga Y, Yoshino O, Hirota Y, Ruimeng X, Hirata T, Takeda S, Yano T, Tsutsumi O, Taketani Y. Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia. *J Clin Endocrinol Metab.* 2003; 88:2348–51. [PubMed: 12727995]
24. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, et al. Circulating angiogenic factors and the risk of preeclampsia. *N Engl J Med.* 2004; 350:672–83. [PubMed: 14764923]
25. Chaiworapongsa T, Romero R, Espinoza J, Bujold E, Mee KY, Goncalves LF, Gomez R, Edwin S. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award *Am J Obstet Gynecol.* 2004; 190:1541–7.
26. Nagamatsu T, Fujii T, Kusumi M, Zou L, Yamashita T, Osuga Y, Momoeda M, Kozuma S, Taketani Y. Cytotrophoblasts up-regulate soluble fms-like tyrosine kinase-1 expression under

- reduced oxygen: an implication for the placental vascular development and the pathophysiology of preeclampsia. *Endocrinology*. 2004; 145:4838–45. [PubMed: 15284201]
27. Ahmad S, Ahmed A. Antiangiogenic effect of soluble vascular endothelial growth factor receptor-1 in placental angiogenesis. *Endothelium*. 2005; 12:89–95. [PubMed: 16036320]
 28. Chaiworapongsa T, Romero R, Kim YM, Kim GJ, Kim MR, Espinoza J, Bujold E, Goncalves L, Gomez R, Edwin S, et al. Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia. *J Matern Fetal Neonatal Med*. 2005; 17:3–18. [PubMed: 15804781]
 29. Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim YM, Bdolah Y, Lim KH, Yuan HT, Libermann TA, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. *Nat Med*. 2006; 12:642–9. [PubMed: 16751767]
 30. Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, Sibai BM, Epstein FH, Romero R, Thadhani R, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. *N Engl J Med*. 2006; 355:992–1005. [PubMed: 16957146]
 31. Vatten LJ, Eskild A, Nilsen TI, Jeansson S, Jenum PA, Staff AC. Changes in circulating level of angiogenic factors from the first to second trimester as predictors of preeclampsia. *Am J Obstet Gynecol*. 2007; 196:239–6. [PubMed: 17346536]
 32. Romero R, Nien JK, Espinoza J, Todem D, Fu W, Chung H, Kusanovic JP, Gotsch F, Erez O, Mazaki-Tovi S, et al. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. *J Matern Fetal Neonatal Med*. 2008; 21:9–23. [PubMed: 18175241]
 33. Erez O, Romero R, Espinoza J, Fu W, Todem D, Kusanovic JP, Gotsch F, Edwin S, Nien JK, Chaiworapongsa T, et al. The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age. *J Matern Fetal Neonatal Med*. 2008; 21:279–87. [PubMed: 18446652]
 34. Stepan H. Angiogenic factors and pre-eclampsia: an early marker is needed. *Clin Sci (Lond)*. 2009; 116:231–2. [PubMed: 19032146]
 35. Kusanovic JP, Romero R, Chaiworapongsa T, Erez O, Mittal P, Vaisbuch E, Mazaki-Tovi S, Gotsch F, Edwin SS, Gomez R, et al. A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia. *J Matern Fetal Neonatal Med*. 2009; 22:1021–38. [PubMed: 19900040]
 36. Chaiworapongsa T, Romero R, Kusanovic JP, Mittal P, Kim SK, Gotsch F, Than NG, Mazaki-Tovi S, Vaisbuch E, Erez O, et al. Plasma soluble endoglin concentration in pre-eclampsia is associated with an increased impedance to flow in the maternal and fetal circulations. *Ultrasound Obstet Gynecol*. 2010; 35:155–62. [PubMed: 20101637]
 37. Ogge G, Chaiworapongsa T, Romero R, Hussein Y, Kusanovic JP, Yeo L, Kim CJ, Hassan SS. Placental lesions associated with maternal underperfusion are more frequent in early-onset than in late-onset preeclampsia. *J Perinat Med*. 2011; 39:641–52. [PubMed: 21848483]
 38. Weed S, Bastek JA, Anton L, Elovitz MA, Parry S, Srinivas SK. Examining the correlation between placental and serum placenta growth factor in preeclampsia. *Am J Obstet Gynecol*. 2012; 207:140–6. [PubMed: 22704767]
 39. Weissgerber TL, Roberts JM, Jeyabalan A, Powers RW, Lee M, Datwyler SA, Gandley RE. Haptoglobin phenotype, angiogenic factors, and preeclampsia risk. *Am J Obstet Gynecol*. 2012; 206:358. [PubMed: 22340942]
 40. Soto E, Romero R, Kusanovic JP, Ogge G, Hussein Y, Yeo L, Hassan SS, Kim CJ, Chaiworapongsa T. Late-onset preeclampsia is associated with an imbalance of angiogenic and anti-angiogenic factors in patients with and without placental lesions consistent with maternal underperfusion. *J Matern Fetal Neonatal Med*. 2012; 25:498–507. [PubMed: 21867402]
 41. Martin JN Jr, Rinehart BK, May WL, Magann EF, Terrone DA, Blake PG. The spectrum of severe preeclampsia: comparative analysis by HELLP (hemolysis, elevated liver enzyme levels, and low platelet count) syndrome classification. *Am J Obstet Gynecol*. 1999; 180:1373–84. [PubMed: 10368474]

42. Romero R, Mazor M, Lockwood CJ, Emamian M, Belanger KP, Hobbins JC, Duffy T. Clinical significance, prevalence, and natural history of thrombocytopenia in pregnancy-induced hypertension. *Am J Perinatol.* 1989; 6:32–8. [PubMed: 2783368]
43. Romero R, Vizoso J, Emamian M, Duffy T, Riely C, Halford T, Oyarzun E, Naftolin F, Hobbins JC. Clinical significance of liver dysfunction in pregnancy-induced hypertension. *Am J Perinatol.* 1988; 5:146–51. [PubMed: 3348861]
44. Belfort M, Van VT, White GL, Kofford S, Allred J, Postma I, Varner M. Low Maternal Middle Cerebral Artery Doppler Resistance Indices Can Predict Future Development of Preeclampsia. *Ultrasound Obstet Gynecol.* 2011
45. Kobayashi T, Terao T. Preeclampsia as chronic disseminated intravascular coagulation. Study of two parameters: thrombin-antithrombin III complex and D-dimers. *Gynecol Obstet Invest.* 1987; 24:170–8. [PubMed: 3319818]
46. Lindheimer MD, Taler SJ, Cunningham FG. Hypertension in pregnancy. *J Am Soc Hypertens.* 2010; 4:68–78. [PubMed: 20400051]
47. Melchiorre K, Thilaganathan B. Maternal cardiac function in preeclampsia. *Curr Opin Obstet Gynecol.* 2011; 23:440–7. [PubMed: 21986727]
48. Parrish MR, Laye MR, Wood T, Keiser SD, Owens MY, May WL, Martin JN. Impedance Cardiography Facilitates Differentiation of Severe and Superimposed Preeclampsia from Other Hypertensive Disorders. *Hypertens Pregnancy.* 2010
49. Riskin-Mashiah S, Belfort MA, Saade GR, Herd AJ. Side-to-side differences in transcranial Doppler parameters in normotensive and preeclamptic pregnant women. *Am J Obstet Gynecol.* 2004; 190:194–8. [PubMed: 14749659]
50. Barton JR, Sibai BM. Gastrointestinal complications of pre-eclampsia. *Semin Perinatol.* 2009; 33:179–88. [PubMed: 19464509]
51. Weinstein L. Syndrome of hemolysis, elevated liver enzymes, and low platelet count: a severe consequence of hypertension in pregnancy. *Am J Obstet Gynecol.* 1982; 142:159–67. [PubMed: 7055180]
52. MacKenna J, Dover NL, Brame RG. Preeclampsia associated with hemolysis, elevated liver enzymes, and low platelets--an obstetric emergency? *Obstet Gynecol.* 1983; 62:751–4. [PubMed: 6634002]
53. Martin JN Jr, Blake PG, Perry KG Jr, McCaul JF, Hess LW, Martin RW. The natural history of HELLP syndrome: patterns of disease progression and regression. *Am J Obstet Gynecol.* 1991; 164:1500–9. [PubMed: 2048596]
54. de Boer K, Buller HR, ten Cate JW, Treffers PE. Coagulation studies in the syndrome of haemolysis, elevated liver enzymes and low platelets. *Br J Obstet Gynaecol.* 1991; 98:42–7. [PubMed: 1998631]
55. Patten IS, Rana S, Shahul S, Rowe GC, Jang C, Liu L, Hacker MR, Rhee JS, Mitchell J, Mahmood F, et al. Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. *Nature.* 2012; 485:333–8. [PubMed: 22596155]
56. Hinchey J, Chaves C, Appignani B, Breen J, Pao L, Wang A, Pessin MS, Lamy C, Mas JL, Caplan LR. A reversible posterior leukoencephalopathy syndrome. *N Engl J Med.* 1996; 334:494–500. [PubMed: 8559202]
57. Oehm E, Hetzel A, Els T, Berlis A, Keck C, Will HG, Reinhard M. Cerebral hemodynamics and autoregulation in reversible posterior leukoencephalopathy syndrome caused by pre-/eclampsia. *Cerebrovasc Dis.* 2006; 22:204–8. [PubMed: 16766873]
58. Melchiorre K, Sutherland GR, Baltabaeva A, Liberati M, Thilaganathan B. Maternal cardiac dysfunction and remodeling in women with preeclampsia at term. *Hypertension.* 2011; 57:85–93. [PubMed: 21098311]
59. Reuwer AQ, Reuwer PJ, van der Post JA, Cramer MJ, Kastelein JJ, Twickler MT. Prolactin fragmentation by trophoblastic matrix metalloproteinases as a possible contributor to peripartum cardiomyopathy and pre-eclampsia. *Med Hypotheses.* 2010; 74:348–52. [PubMed: 19748190]
60. Escher G, Mohaupt M. Role of aldosterone availability in preeclampsia. *Mol Aspects Med.* 2007; 28:245–54. [PubMed: 17512581]

61. Romero R, Kusanovic JP, Chaiworapongsa T, Hassan SS. Placental bed disorders in preterm labor, preterm PROM, spontaneous abortion and abruptio placentae. *Best Pract Res Clin Obstet Gynaecol.* 2011; 25:313–27. [PubMed: 21388889]
62. Ananth CV, Vintzileos AM. Ischemic placental disease: epidemiology and risk factors. *Eur J Obstet Gynecol Reprod Biol.* 2011; 159:77–82. [PubMed: 21839575]
63. Drewlo S, Czikk M, Baczyk D, Lye S, Kingdom J. Glial cell missing-1 mediates over-expression of tissue inhibitor of metalloproteinase-4 in severe pre-eclamptic placental villi. *Hum Reprod.* 2011; 26:1025–34. [PubMed: 21406447]
64. American College of Obstetricians and Gynecologists. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. *Int J Gynaecol Obstet.* 2002; 77:67–75. [PubMed: 12094777]
65. Hirashima C, Ohkuchi A, Takahashi K, Suzuki H, Yoshida M, Ohmaru T, Eguchi K, Ariga H, Matsubara S, Suzuki M. Gestational hypertension as a subclinical preeclampsia in view of serum levels of angiogenesis-related factors. *Hypertens Res.* 2011; 34:212–7. [PubMed: 21048778]
66. Liu CM, Cheng PJ, Chang SD. Maternal complications and perinatal outcomes associated with gestational hypertension and severe preeclampsia in Taiwanese women. *J Formos Med Assoc.* 2008; 107:129–38. [PubMed: 18285245]
67. Walker RL, Hemmelgarn B, Quan H. Incidence of gestational hypertension in the Calgary Health Region from 1995 to 2004. *Can J Cardiol.* 2009; 25:e284–e287. [PubMed: 19668790]
68. Homer CS, Brown MA, Mangos G, Davis GK. Non-proteinuric pre-eclampsia: a novel risk indicator in women with gestational hypertension. *J Hypertens.* 2008; 26:295–302. [PubMed: 18192844]
69. donald-Wallis C, Lawlor DA, Heron J, Fraser A, Nelson SM, Tilling K. Relationships of risk factors for pre-eclampsia with patterns of occurrence of isolated gestational proteinuria during normal term pregnancy. *PLoS One.* 2011; 6:e22115. [PubMed: 21789220]
70. Morikawa M, Yamada T, Minakami H. Outcome of pregnancy in patients with isolated proteinuria. *Curr Opin Obstet Gynecol.* 2009; 21:491–5. [PubMed: 19633554]
71. Holston AM, Qian C, Yu KF, Epstein FH, Karumanchi SA, Levine RJ. Circulating angiogenic factors in gestational proteinuria without hypertension. *Am J Obstet Gynecol.* 2009; 200:392–10. [PubMed: 19168169]
72. Ohkuchi A, Hirashima C, Matsubara S, Suzuki H, Takahashi K, Usui R, Suzuki M. Serum sFlt1:PIGF ratio, PIGF, and soluble endoglin levels in gestational proteinuria. *Hypertens Pregnancy.* 2009; 28:95–108. [PubMed: 19165674]
73. Morikawa M, Yamada T, Yamada T, Cho K, Yamada H, Sakuragi N, Minakami H. Pregnancy outcome of women who developed proteinuria in the absence of hypertension after mid-gestation. *J Perinat Med.* 2008; 36:419–24. [PubMed: 18605971]
74. Sibai BM, Stella CL. Diagnosis and management of atypical preeclampsia-eclampsia. *Am J Obstet Gynecol.* 2009; 200:481–7. [PubMed: 19019323]
75. Aarnoudse JG, Houthoff HJ, Weits J, Vellenga E, Huisjes HJ. A syndrome of liver damage and intravascular coagulation in the last trimester of normotensive pregnancy. A clinical and histopathological study. *Br J Obstet Gynaecol.* 1986; 93:145–55. [PubMed: 3511956]
76. Goodlin RC. Severe pre-eclampsia: another great imitator. *Am J Obstet Gynecol.* 1976; 125:747–53. [PubMed: 945695]
77. Bailey DJ, Walton SM. Routine investigations might be useful in pre-eclampsia, but not in gestational hypertension. *Aust N Z J Obstet Gynaecol.* 2005; 45:144–7. [PubMed: 15760317]
78. Saudan P, Brown MA, Buddle ML, Jones M. Does gestational hypertension become pre-eclampsia? *Br J Obstet Gynaecol.* 1998; 105:1177–84. [PubMed: 9853766]
79. Milne F, Redman C, Walker J, Baker P, Black R, Blincoe J, Cooper C, Fletcher G, Jokinen M, Moran PA, et al. Assessing the onset of pre-eclampsia in the hospital day unit: summary of the pre-eclampsia guideline (PRECOG II). *BMJ.* 2009; 339:b3129. [PubMed: 19740933]
80. Sibai BM. Evaluation and management of severe preeclampsia before 34 weeks' gestation. *Am J Obstet Gynecol.* 2011; 205:191–8. [PubMed: 22071049]
81. Sibai BM. Diagnosis and management of gestational hypertension and preeclampsia. *Obstet Gynecol.* 2003; 102:181–92. [PubMed: 12850627]

82. Anumba DO, Lincoln K, Robson SC. Predictive value of clinical and laboratory indices at first assessment in women referred with suspected gestational hypertension. *Hypertens Pregnancy*. 2010; 29:163–79. [PubMed: 20367506]
83. Thangaratinam S, Ismail KM, Sharp S, Coomarasamy A, Khan KS. Accuracy of serum uric acid in predicting complications of pre-eclampsia: a systematic review. *BJOG*. 2006; 113:369–78. [PubMed: 16553648]
84. Menzies J, Magee LA, MacNab YC, Ansermino JM, Li J, Douglas MJ, Gruslin A, Kyle P, Lee SK, Moore MP, et al. Current CHS and NHBPEP criteria for severe preeclampsia do not uniformly predict adverse maternal or perinatal outcomes. *Hypertens Pregnancy*. 2007; 26:447–62. [PubMed: 18066963]
85. Bell SC, Halligan AW, Martin A, Ashmore J, Shennan AH, Lambert PC, Taylor DJ. The role of observer error in antenatal dipstick proteinuria analysis. *Br J Obstet Gynaecol*. 1999; 106:1177–80. [PubMed: 10549963]
86. Bellomo G, Venanzi S, Saronio P, Verdura C, Narducci PL. Prognostic significance of serum uric acid in women with gestational hypertension. *Hypertension*. 2011; 58:704–8. [PubMed: 21876075]
87. van der Tuuk K, Koopmans CM, Groen H, Aarnoudse JG, van den Berg PP, van Beek JJ, Copraij FJ, Kleiverda G, Porath M, Rijnders RJ, et al. Prediction of progression to a high risk situation in women with gestational hypertension or mild pre-eclampsia at term. *Aust N Z J Obstet Gynaecol*. 2011; 51:339–46. [PubMed: 21806572]
88. Thornton CE, Makris A, Ogle RF, Tooher JM, Hennessy A. Role of proteinuria in defining pre-eclampsia: clinical outcomes for women and babies. *Clin Exp Pharmacol Physiol*. 2010; 37:466–70. [PubMed: 19930427]
89. Paula LG, da Costa BE, Poli-de-Figueiredo CE, Antonello IC. Does uric acid provide information about maternal condition and fetal outcome in pregnant women with hypertension? *Hypertens Pregnancy*. 2008; 27:413–20. [PubMed: 19003642]
90. Martin JN Jr, May WL, Magann EF, Terrone DA, Rinehart BK, Blake PG. Early risk assessment of severe preeclampsia: admission battery of symptoms and laboratory tests to predict likelihood of subsequent significant maternal morbidity. *Am J Obstet Gynecol*. 1999; 180:1407–14. [PubMed: 10368478]
91. Haddad B, Barton JR, Livingston JC, Chahine R, Sibai BM. Risk factors for adverse maternal outcomes among women with HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome. *Am J Obstet Gynecol*. 2000; 183:444–8. [PubMed: 10942484]
92. Cavkaytar S, Ugurlu EN, Karaer A, Tapisiz OL, Danisman N. Are clinical symptoms more predictive than laboratory parameters for adverse maternal outcome in HELLP syndrome? *Acta Obstet Gynecol Scand*. 2007; 86:648–51. [PubMed: 17520393]
93. Witlin AG, Saade GR, Mattar F, Sibai BM. Risk factors for abruptio placentae and eclampsia: analysis of 445 consecutively managed women with severe preeclampsia and eclampsia. *Am J Obstet Gynecol*. 1999; 180:1322–9. [PubMed: 10368466]
94. Ganzevoort W, Rep A, Bonsel GJ, de Vries JI, Wolf H. Dynamics and incidence patterns of maternal complications in early-onset hypertension of pregnancy. *BJOG*. 2007; 114:741–50. [PubMed: 17516967]
95. Oney T, Meyer-Sabellek W. Variability of arterial blood pressure in normal and hypertensive pregnancy. *J Hypertens Suppl*. 1990; 8:S77–S81. [PubMed: 2082002]
96. Lindheimer MD, Kanter D. Interpreting abnormal proteinuria in pregnancy: the need for a more pathophysiological approach. *Obstet Gynecol*. 2010; 115:365–75. [PubMed: 20093912]
97. Nisell H, Palm K, Wolff K. Prediction of maternal and fetal complications in preeclampsia. *Acta Obstet Gynecol Scand*. 2000; 79:19–23. [PubMed: 10646811]
98. Sibai BM, Barton JR. Expectant management of severe preeclampsia remote from term: patient selection, treatment, and delivery indications. *Am J Obstet Gynecol*. 2007; 196:514–9. [PubMed: 17547875]
99. Odendaal HJ, Pattinson RC, du TR. Fetal and neonatal outcome in patients with severe pre-eclampsia before 34 weeks. *S Afr Med J*. 1987; 71:555–8. [PubMed: 3576400]

100. Ganzevoort W, Rep A, de Vries JI, Bonsel GJ, Wolf H. Prediction of maternal complications and adverse infant outcome at admission for temporizing management of early-onset severe hypertensive disorders of pregnancy. *Am J Obstet Gynecol.* 2006; 195:495–503. [PubMed: 16643825]
101. Gazmararian JA, Petersen R, Jamieson DJ, Schild L, Adams MM, Deshpande AD, Franks AL. Hospitalizations during pregnancy among managed care enrollees. *Obstet Gynecol.* 2002; 100:94–100. [PubMed: 12100809]
102. Bacak SJ, Callaghan WM, Dietz PM, Crouse C. Pregnancy-associated hospitalizations in the United States, 1999–2000. *Am J Obstet Gynecol.* 2005; 192:592–7. [PubMed: 15696008]
103. Callaghan WM, MacKay AP, Berg CJ. Identification of severe maternal morbidity during delivery hospitalizations, United States, 1991–2003. *Am J Obstet Gynecol.* 2008; 199:133–8. [PubMed: 18279820]
104. Liu S, Heaman M, Sauve R, Liston R, Reyes F, Bartholomew S, Young D, Kramer MS. An analysis of antenatal hospitalization in Canada, 1991–2003. *Matern Child Health J.* 2007; 11:181–7. [PubMed: 17089198]
105. Brooten D, Kaye J, Poutasse SM, Nixon-Jensen A, McLean H, Brooks LM, Groden S, Polis NS, Youngblut JM. Frequency, timing, and diagnoses of antenatal hospitalizations in women with high-risk pregnancies. *J Perinatol.* 1998; 18:372–6. [PubMed: 9766414]
106. Chaiworapongsa T, Romero R, Savasan ZA, Kusanovic JP, Ogge G, Soto E, Dong Z, Tarca A, Gaurav B, Hassan SS. Maternal plasma concentrations of angiogenic/anti-angiogenic factors are of prognostic value in patients presenting to the obstetrical triage area with the suspicion of preeclampsia. *J Matern Fetal Neonatal Med.* 2011; 24:1187–207. [PubMed: 21827221]
107. Stoll BJ, Hansen NI, Bell EF, Shankaran S, Laptook AR, Walsh MC, Hale EC, Newman NS, Schibler K, Carlo WA, et al. Neonatal outcomes of extremely preterm infants from the NICHD Neonatal Research Network. *Pediatrics.* 2010; 126:443–56. [PubMed: 20732945]
108. Clark RH. The epidemiology of respiratory failure in neonates born at an estimated gestational age of 34 weeks or more. *J Perinatol.* 2005; 25:251–7. [PubMed: 15605071]
109. Papile LA, Burstein J, Burstein R, Koffler H. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. *J Pediatr.* 1978; 92:529–34. [PubMed: 305471]
110. Jobe AH, Bancalari E. Bronchopulmonary dysplasia. *Am J Respir Crit Care Med.* 2001; 163:1723–9. [PubMed: 11401896]
111. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. *Biometrics.* 1988; 44:837–45. [PubMed: 3203132]
112. Rana S, Powe CE, Salahuddin S, Verlohren S, Perschel FH, Levine RJ, Lim KH, Wenger JB, Thadhani R, Karumanchi SA. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. *Circulation.* 2012; 125:911–9. [PubMed: 22261192]
113. Pencina MJ, D'Agostino RB Sr. Thoroughly modern risk prediction? *Sci Transl Med.* 2012; 4:131fs10.
114. von Dadelszen P, Payne B, Li J, Ansermino JM, Broughton PF, Cote AM, Douglas MJ, Gruslin A, Hutcheon JA, Joseph KS, et al. Prediction of adverse maternal outcomes in pre-eclampsia: development and validation of the fullPIERS model. *Lancet.* 2011; 377:219–27. [PubMed: 21185591]
115. Sibude J, Guibourdenche J, Dionne MD, Le RC, Anselem O, Serreau R, Goffinet F, Tsatsaris V. Placental growth factor for the prediction of adverse outcomes in patients with suspected preeclampsia or intrauterine growth restriction. *PLoS One.* 2012; 7:e50208. [PubMed: 23209675]
116. Moore AG, Young H, Keller JM, Ojo LR, Yan J, Simas TA, Maynard SE. Angiogenic biomarkers for prediction of maternal and neonatal complications in suspected preeclampsia. *J Matern Fetal Neonatal Med.* 2012; 25:2651–7. [PubMed: 22861812]
117. Cook NR. Use and misuse of the receiver operating characteristic curve in risk prediction. *Circulation.* 2007; 115:928–35. [PubMed: 17309939]
118. Hlatky MA, Greenland P, Arnett DK, Ballantyne CM, Criqui MH, Elkind MS, Go AS, Harrell FE Jr, Hong Y, Howard BV, et al. Criteria for evaluation of novel markers of cardiovascular risk: a

- scientific statement from the American Heart Association. *Circulation*. 2009; 119:2408–16. [PubMed: 19364974]
119. Cook NR. Statistical evaluation of prognostic versus diagnostic models: beyond the ROC curve. *Clin Chem*. 2008; 54:17–23. [PubMed: 18024533]
120. Molvarec A, Szarka A, Walentin S, Szucs E, Nagy B, Rigo J Jr. Circulating angiogenic factors determined by electrochemiluminescence immunoassay in relation to the clinical features and laboratory parameters in women with pre-eclampsia. *Hypertens Res*. 2010; 33:892–8. [PubMed: 20535121]
121. Ohkuchi A, Hirashima C, Suzuki H, Takahashi K, Yoshida M, Matsubara S, Suzuki M. Evaluation of a new and automated electrochemiluminescence immunoassay for plasma sFlt-1 and PlGF levels in women with preeclampsia. *Hypertens Res*. 2010; 33:422–7. [PubMed: 20150910]
122. Schiettecatte J, Russcher H, Anckaert E, Mees M, Leeser B, Tirelli AS, Fiedler GM, Luthe H, Denk B, Smits J. Multicenter evaluation of the first automated Elecsys sFlt-1 and PlGF assays in normal pregnancies and preeclampsia. *Clin Biochem*. 2010; 43:768–70. [PubMed: 20206155]
123. Verloren S, Galindo A, Schlembach D, Zeisler H, Herraiz I, Moertl MG, Pape J, Dudenhausen JW, Denk B, Stepan H. An automated method for the determination of the sFlt-1/PlGF ratio in the assessment of preeclampsia. *Am J Obstet Gynecol*. 2010; 202:161. [PubMed: 19850276]

Figure 1.

Median maternal plasma Multiple of Median (MoM) concentrations of soluble vascular endothelial growth factor receptor (sVEGFR)-1, soluble endoglin (sEng), sVEGFR-2, placental growth factor (PIGF), PIGF/sVEGFR-1 ratio and PIGF/sEng ratio in patients who subsequently developed severe PE requiring preterm delivery and those who remained stable until term [sVEGFR-1: median 4.46 MoM, interquartile range (IQR) 2.5–9.8 MoM vs. 1.5 MoM, IQR 0.9–2.4 MoM; $p < 0.001$; sEng: median 3.3 MoM, IQR 2.1–5.6 MoM vs. 1.2 MoM, IQR 0.9–1.7 MoM; $p < 0.001$; sVEGFR-2: median 0.69 MoM, IQR 0.5–0.9 MoM vs. 0.9 MoM, IQR 0.7–1.1 MoM; $p < 0.001$; PIGF: median 0.15 MoM, IQR 0.08–0.23 MoM vs. 0.47 MoM, IQR 0.3–1.1 MoM; $p < 0.001$; PIGF/sVEGFR-1: median 0.03 MoM, IQR 0.008–0.07 MoM vs. 0.4 MoM, IQR 0.2–0.9 MoM; $p < 0.001$; PIGF/sEng: median 0.04 MoM, IQR 0.01–0.09 MoM vs. 0.4 MoM, IQR 0.2–0.9 MoM; $p < 0.001$].

Figure 2. Area under the Receiver-Operating Characteristic (ROC) curves for angiogenic/anti-angiogenic factor ratio Multiples of the Median (MoM) compared to mean arterial pressure and combined standard tests (mean arterial pressure, serum creatinine, serum uric acid, aspartate aminotransferase, platelet count) for the identification of patients who delivered within 2 weeks; A-Restricted to patients who presented before 34 weeks of gestation; and B- Included all patients in the cohort

Figure 3.

Addition of the PIGF/sVEGFR-1 ratio to standard tests significantly improved the sensitivity at a fixed false-positive rate of 3% ($p=0.004$) and marginally improved sensitivity at a fixed false-positive rate of 5% ($p=0.06$) for the identification of patients who would be delivered due to preeclampsia within two weeks.

Figure 4.

Kaplan-Meier survival curves by angiogenic/anti-angiogenic ratio Multiple of Median (MoM) cut-offs of patients who delivered prior to 37 weeks of gestation (right censored). Patients who delivered preterm due to causes other than PE had the interval between blood draw and delivery treated as a censored observation. (A= PIGF/sVEGFR-1; B= PIGF/sEng).

Table 1
Demographic/clinical characteristics, maternal morbidity and adverse neonatal outcome by study groups

	Stable until delivery at term (n=37)	Developed PE requiring preterm delivery (n=48)	p
Age (years)	26 (19.5–32.5)	26.5 (21.0–33.8)	0.6
African American	34 (91.9%)	44 (91.7%)	0.9
Nulliparous	16 (43.2%)	20 (41.7%)	0.8
Previous preeclampsia	7/21 (33.3%)	12/28 (42.9%)	0.5
Smoking	6 (16.2%)	5 (10.4%)	0.4
Body mass index (Kg/m ²)	32.0 ± 7.7	30.9±8.2 ^a	0.5
Chronic hypertension	18 (48.6%)	22(45.8%)	0.8
Pregestational diabetes	2 (5.4%)	3 (6.3%)	0.9
Chief complaint in triage area			
Elevated blood pressure	31 (84%)	47 (97.9%)	0.04
Proteinuria	8 (21.6%)	10 (20.8%)	0.9
Edema	2 (5.4%)	7 (14.6%)	0.3
Headache	15 (40.5%)	22 (45.8%)	0.6
GA at venipuncture (weeks)	35.0 (32.3–35.9)	32.9 (30.1–35.4)	0.1
Average blood pressure in triage area			
Systolic (mmHg)	135 ± 11	158 ± 16	<0.001
Diastolic (mmHg)	82 ± 8	97 ± 11	<0.001
Mean arterial (mmHg)	100±8	117±11	<0.001
Proteinuria in triage area	11 (29.7%)	37 (77.1%)	<0.001
Interval to delivery (days)	25 (13–46)	3 (1–9)	<0.001
GA at delivery (weeks)	38.3 (37.1–39.0)	34.7 (32.1–36.1)	<0.001

	Stable until delivery at term (n=37)	Developed PE requiring preterm delivery (n=48)	p
Birthweight (grams)	3056 ± 483	1866 ± 625	<0.001
< 10%	6 (16.2%)	19 (39.6%)	0.02
Adverse maternal and neonatal outcome			
Indicated preterm delivery < 34 weeks	--	20 (41.7%)	<0.001
<u>Fetal death</u>	1 (2.1%)	--	0.4
<u>Maternal morbidity</u>			
Eclampsia (at term)	1 (2.7%)	--	0.4
HELLP	--	1 (2.1%)	1.0
Pulmonary edema	--	2 (4.2%)	0.5
Oliguria	--	6 (12.5%)	0.03
Serum Creatinine >1.2 mg/dL	--	5 (10.4%)	0.06
Placenta abruptio	2 (5.4%)	5 (10.4%)	0.5
Elevated AST	3 (8.1%)	7 (14.6%)	0.5
Thrombocytopenia	--	3 (6.3%)	0.3
Antepartum admission to ICU	--	7 (14.6%)	0.02
Composite adverse maternal outcome	5 (13.5%)	24 (50%)	<0.001
<u>Neonatal complications</u>			
Fetal or neonatal death	1 (2.1%)	--	0.4
RDS	3 (8.1%)	8 (16.7%)	0.3
BPD	--	3 (6.3%)	0.2
IVH	2 (5.4%)	4 (8.3%)	0.5
Adverse neonatal outcome	4 (10.8%)	10 (20.8%)	0.2
Composite maternal morbidity and/or adverse neonatal outcome	8 (21.6%)	29 (60.4%)	<0.001

^a: n=47; value expressed as median (interquartile), mean ± SD or number (%)

PE=pre-eclampsia; GA=gestational age; AST= aspartate aminotransferase; ICU= intensive care unit; RDS= respiratory distress syndrome; BPD= bronchopulmonary dysplasia; IVH=intraventricular hemorrhage

Three patients in Group I delivered preterm: two due to spontaneous preterm delivery, and another one due to anti-D isimmunization. One patient in Group I was diagnosed with chronic hypertension and superimposed preeclampsia at 35 weeks and 4 days. She was discharged home on the same day and had placental abruption with a fetal death at 37 6/7 weeks

Diagnostic performance of plasma concentrations of angiogenic/anti-angiogenic factors for the identification of patients who subsequently developed severe preeclampsia requiring preterm delivery

Table II

	Cut-off (MoM) from ROC curves in previous publication	Sensitivity (%)	Specificity (%)	LR for a positive test (95% CI)	Posterior probability (95% CI)	LR of a negative test (95% CI)	Posterior probability (95% CI)
sVEGFR-1	3.46	58.3 (28/48)	86.5 (32/37)	4.3 (1.9–10)	85% (71–93)	0.48 (0.3–0.7)	38% (31–47)
sEng	2.7	64.6 (31/48)	91.9 (34/37)	7.9 (2.6–24)	91% (77–97)	0.39 (0.3–0.6)	34% (25–43)
PlGF	0.4	91.7 (44/48)	62.2 (23/37)	2.4 (1.6–3.7)	76% (67–83)	0.13 (0.05–0.4)	14% (6–31)
sVEGFR-2	0.74	56.3 (27/48)	67.6 (25/37)	1.7 (1.02–2.9)	69% (57–79)	0.65 (0.4–0.9)	46% (36–55)
PlGF/sVEGFR-1	0.05	66.7 (32/48)	91.9 (34/37)	8.2 (2.7–25)	91% (78–97)	0.36 (0.2–0.6)	32% (24–42)
PlGF/sEng	0.07	66.7 (32/48)	91.9 (34/37)	8.2 (2.7–25)	91% (78–97)	0.36 (0.2–0.6)	32% (24–42)

Prevalence of severe preeclampsia requiring preterm delivery =56.5% (48/85)

Value expressed as % (n/N)

MoM= multiples of the median; ROC= receiver-operating characteristic; LR= Likelihood Ratio; CI= confidence interval

PlGF= Placental Growth Factor, sEng= soluble endoglin, sVEGFR-1=soluble vascular endothelial growth factor receptor-1, sVEGFR-2=soluble vascular endothelial growth factor receptor-2

Table III
Likelihood (unadjusted and adjusted) of each outcome according to angiogenic/antiangiogenic factors ratio

Outcome - Predictor	Outcome				Unadjusted		Adjusted-I (Full)		Adjusted-II (Reduced)				
	No		Yes		OR	95% CI	OR	95% CI	OR	95% CI			
			n/N	%							n/N		
Indicated Preterm Delivery due to PE													
PIGF/sVEGFR-1 MoM 0.05	8.1	3/37	66.7	32/48	22.7	6.0	85.2	7.1	1.3	39.7	7.4*	1.6	34.1
PIGF/sEng MoM 0.07	8.1	3/37	66.7	32/48	22.7	6.0	85.2	8.0	1.5	42.9	8.8*	1.9	40.2
Maternal morbidity													
PIGF/sVEGFR-1 MoM 0.05	32.1	18/56	58.6	17/29	3.0	1.2	7.6	2.2	0.7	7.3	3.7 α	1.4	10.0
PIGF/sEng MoM 0.07	32.1	18/56	58.6	17/29	3.0	1.2	7.6	2.3	0.7	7.1	2.4 β	0.8	7.3
Adverse neonatal outcome													
PIGF/sVEGFR-1 MoM 0.05	33.8	24/71	78.6	11/14	7.2	1.8	28.2	6.4	0.9	44.9	10.0 γ	2.0	48.9
PIGF/sEng MoM 0.07	33.8	24/71	78.6	11/14	7.2	1.8	28.2	5.9	0.9	37.7	10.1 γ	2.1	49.8
Composite maternal morbidity and/or adverse neonatal outcome													
PIGF/sVEGFR-1 MoM 0.05	17.4	4/23	65.0	13/20	8.8	2.1	36.4	8.6	0.8	90.7	2.8*	0.9	8.8
PIGF/sEng MoM 0.07	17.4	4/23	65.0	13/20	8.8	2.1	36.4	5.9	0.8	45.7	3.1*	1.0	9.5

OR=Odds Ratio, CI= Confidence Interval

PE= preeclampsia, PIGF= Placental Growth Factor, sEng= soluble endoglin, sVEGFR-1=soluble vascular endothelial growth factor receptor-1; ORs represent the likelihood of outcome among subjects exhibiting analyte ratio concentrations below centile cutoff relative to the likelihood of outcome among subjects at or above cutoff ; Adjusted-I (Full) models included age, African American ethnicity, chronic hypertension, mean arterial pressure, and combined nulliparity/ previous preeclampsia; Adjusted-II (Reduced) models include final multivariable adjustment after excluding factors that were not significantly associated with the dependent variable from the Full model-variables included are indicated as follows:

* adjusted for average mean arterial pressure

^a : adjusted for nulliparity, previous preeclampsia

^b : adjusted for nulliparity, previous preeclampsia, average mean arterial pressure

γ ; adjusted for gestational age at blood sampling

NIH-PA Author Manuscript

NIH-PA Author Manuscript

NIH-PA Author Manuscript

Demographic/clinical characteristics and adverse maternal and neonatal outcomes of the patients who presented to the triage area at < 34 weeks according to interval to delivery within and more than 2 weeks

Table IV

	Delivery more than 2 weeks (n=25)	Delivery within 2 weeks (n=18)	p
Age (years)	29 (20–36)	24.5 (19–31)	0.1
African American	23 (92.0%)	16 (88.9%)	1.0
Nulliparous	11 (44.0%)	9 (50.0%)	0.8
Previous preeclampsia	4/14 (28.6%)	5/9 (55.6%)	0.4
Smoking	3 (12.0%)	1 (5.6%)	0.6
Body mass index (Kg/m ²)	34.0 ± 7.1	31.2±9.5	0.4
Chronic hypertension	16 (64.0%)	7(38.9%)	0.1
Pre-gestational diabetes	1 (4.0%)	0	1.0
Chief complaint in triage area			
Elevated blood pressure	22 (88%)	18 (100%)	0.3
Proteinuria	7 (28.0%)	4 (22.2%)	0.7
Edema	2 (8.0%)	1 (5.6%)	1.0
Headache	10 (40.0%)	7 (38.9%)	0.9
GA at blood sampling (weeks)	30.6 (27.6–33.0)	31.5 (29.0–32.3)	0.9
Average blood pressure in triage area			
Systolic (mmHg)	145 ±17	160 ±18	0.005
Diastolic (mmHg)	85 ± 9	102 ± 14	<0.001
Mean arterial (mmHg)	105±8	117±11	<0.001
Proteinuria in triage area	3 (20%)	19 (67.9%)	0.003
Platelet count	237 (190–278)	192 (172–235)	0.09
AST	19 (14–34)	23 (18–34)	0.1
Serum Creatinine (mg/dL)	0.6 (0.6–0.7)	0.7 (0.6–0.7)	0.08

	Delivery more than 2 weeks (n=25)	Delivery within 2 weeks (n=18)	p
Serum Uric acid (mg/dL)	3.4 (3.0–3.8) ^a	4.9 (3.9–5.5) ^β	0.001
Hospitalized	15 (60%)	18 (100%)	0.002
Interval to delivery (days)	41 (22–65)	3 (2–6)	<0.001
GA at delivery (weeks)	37 (35.3–38.9)	32 (29.7–32.7)	<0.001
Birthweight (grams)	2767 ± 730	1283 ± 384	<0.001
adverse maternal and neonatal outcomes			
Indicated preterm delivery < 34 weeks			
Maternal morbidity at 2 weeks			
Eclampsia	--	18 (100%)	<0.001
HELLP	--	--	
Pulmonary edema	--	--	
Oliguria	--	3 (16.7%)	0.06
Serum Creatinine >1.2 mg/dL	--	1 (5.6%)	0.4
Placenta abruptio	--	1 (5.6%)	0.4
Elevated AST	--	4 (22.2%)	0.025
Thrombocytopenia	--	--	--
Antepartum admission to ICU	--	3 (16.7%)	0.06
Fetal Death	--	--	
Composite adverse maternal outcome	--	9 (50%)	<0.001
Neonatal complications at 2 weeks			
Neonatal death	--	--	--
RDS	--	6 (33.3%)	0.003
BPD	--	3 (16.7%)	0.06
IVH	--	3 (16.7%)	0.06
Adverse neonatal outcome	--	8 (44.4%)	<0.001
Composite maternal morbidity and/or adverse neonatal outcome	--	13 (72.2%)	<0.001

Value expressed as median (interquartile), mean ± SD or number (%); GA=gestational age; AST= aspartate aminotransferase; ICU= intensive care unit; RDS= respiratory distress syndrome; BPD= bronchopulmonary dysplasia; IVH=intraventricular hemorrhage

Table V

Diagnostic performance of plasma concentrations of angiogenic/anti-angiogenic factors among patients who presented at < 34 weeks of gestation for the identification of patients who subsequently delivered within 2 weeks

	Cut-off (MoM) derived from ROC curves in previous publication	Sensitivity (%)	Specificity (%)	LR for a positive test (95% CI)	Posterior probability (95% CI)	LR of a negative test (95% CI)	Posterior probability (95% CI)
sVEGFR-1	4.0	78 (14/18)	96 (24/25)	19 (2.8–135)	93% (67–99)	0.23 (0.1–0.6)	14% (7–28)
sEng	3.0	83 (15/18)	96 (24/25)	21 (3.0–144)	94% (69–99)	0.17 (0.06–0.5)	11% (4–26)
PIGF	0.15	72 (13/18)	92 (23/25)	9 (2.3–35)	87% (63–96)	0.3 (0.1–0.6)	18% (9–32)
sVEGFR-2	0.74	72 (13/18)	72 (18/25)	2.6 (1.3–5.2)	65% (48–79)	0.39 (0.2–0.8)	22% (11–38)
PIGF/sVEGFR-1	0.035	89 (16/18)	96 (24/25)	22 (3.2–153)	94% (70–99)	0.12 (0.03–0.4)	8% (2–24)
PIGF/sEng	0.05	89 (16/18)	96 (24/25)	22 (3.0–153)	94% (70–99)	0.12 (0.03–0.4)	8% (2–24)

Prevalence of patients who subsequently delivered within 14 days = 41.9% (18/43)

Value expressed as % (n/N); MoM= multiples of the median; ROC= receiver-operating characteristic; LR= Likelihood Ratio; CI= confidence interval; PIGF= Placental Growth Factor, sEng= soluble endoglin, sVEGFR-1=soluble vascular endothelial growth factor receptor-1, sVEGFR-2=soluble vascular endothelial growth factor receptor-2

Likelihood (unadjusted and adjusted) of selected pregnancy outcomes according to angiogenic/antiangiogenic factor ratio in patients who presented to the triage area at < 34 weeks of gestation

Table VI

Outcome - Predictor	Outcome				Unadjusted			Adjusted		
	No	Yes	OR	95% CI	OR	95% CI	OR	95% CI		
	%	n/N	%	n/N						
Delivery within 2 weeks										
PIGF/sVEGFR-1 MoM 0.035	4	1/25	88.9	16/18	192.0	16.0	>999,999	53.7	5.9	485.8
PIGF/sEng MoM 0.05	4	1/25	88.9	16/18	192.0	16.0	>999,999	58.3	6.3	538.5
Week 2 maternal morbidity										
PIGF/sVEGFR-1 MoM 0.035	26.5	9/34	88.9	8/9	22.2	2.4	203.3	10.1	1.3	80.8
PIGF/sEng MoM 0.05	26.5	9/34	88.9	8/9	22.2	2.4	203.3	9.4	1.2	72.0
Week 2 adverse neonatal outcome										
PIGF/sVEGFR-1 MoM 0.035	25.7	9/35	100	8/8	Insufficient variation to model					
PIGF/sEng MoM 0.05	25.7	9/35	100	8/8						
Week 2 composite maternal morbidity and/or adverse neonatal outcome										
PIGF/sVEGFR-1 MoM 0.035	16.7	5/30	92.3	12/13	60.0	6.3	571.9	19.5	2.5	150.1
PIGF/sEng MoM 0.05	16.7	5/30	92.3	12/13	60.0	6.3	571.9	19.5	2.6	144.1

OR=Odds Ratio, CI= Confidence Interval; PIGF= Placental Growth Factor, sEng= soluble endoglin, sVEGFR-1=soluble vascular endothelial growth factor receptor-1. ORs represent the likelihood of outcome among subjects exhibiting analyte ratio concentrations below centile cutoff relative to the likelihood of outcome among subjects at or above cutoff; Adjusted models included accounted for the association between mean arterial pressure and the outcome variable, Firth's penalized maximum likelihood estimation was also used due to small sample size.

Sensitivities of each outcome according to angiogenic/antiangiogenic factors ratio in patients who presented to the triage area at < 34 weeks of gestation while fixing different false positive rates (FP)

Table VII

Outcome - Predictor	Sensitivities (%) at Fixed False Positive Rates (%)							
	FP: 3%	95% CI	FP: 5%	95% CI	FP: 10%	95% CI	95% CI	
Delivery with 14 Days								
PIGF/sVEGFR-1	72.2	46.5 90.3	88.9	65.3 98.6	88.9	65.3	88.9	98.6
PIGF/sEng	77.8	52.4 93.6	88.9	65.3 98.6	88.9	65.3	88.9	98.6
Systolic blood pressure (mmHg)	22.2	6.4 47.6	44.4	21.5 69.2	44.4	21.5	44.4	69.2
Serum AST	16.7	3.6 41.4	16.7	3.6 41.4	16.7	3.6	16.7	41.4
Serum creatinine (mg/dL)	11.1	1.4 34.7	22.2	6.4 47.6	55.6	30.8	55.6	78.5
Mean arterial pressure (mmHg)	5.6	0.1 27.3	44.4	21.5 69.2	44.4	21.5	44.4	69.2
Diastolic blood pressure (mmHg)	5.6	0.1 27.3	44.4	21.5 69.2	55.6	30.8	55.6	78.5
Serum uric acid (mg/dL)	0.0		11.8	1.5 36.4	70.6	44.0	70.6	89.7
Platelet counts	0.0		0.0		5.6	0.1	5.6	27.3
Proteinuria	0.0		0.0		0.0		0.0	
Week 2 composite maternal morbidity and/or adverse neonatal outcome								
PIGF/sVEGFR-1	46.2	19.2 74.9	92.3	64.0 99.8	92.3	64.0	92.3	99.8
PIGF/sEng	61.5	31.6 86.1	92.3	64.0 99.8	92.3	64.0	92.3	99.8
Serum uric acid (mg/dL)	15.4	1.9 45.4	23.1	5.0 53.8	46.2	19.2	46.2	74.9
Systolic blood pressure (mmHg)	30.8	9.1 61.4	53.8	25.1 80.8	61.5	31.6	61.5	86.1
Diastolic blood pressure (mmHg)	53.8	25.1 80.8	53.8	25.1 80.8	61.5	31.6	61.5	86.1
Mean arterial pressure (mmHg)	15.4	1.9 45.4	53.8	25.1 80.8	61.5	31.6	61.5	86.1
Serum creatinine (mg/dL)	30.8	9.1 61.4	53.8	25.1 80.8	53.8	25.1	53.8	80.8
Serum AST	23.1	5.0 53.8	23.1	5.0 53.8	23.1	5.0	23.1	53.8
Platelet counts	0.0		7.7	0.2 36.0	7.7	0.2	7.7	36.0
Proteinuria	0.0		0.0		0.0		0.0	

PIGF= Placental Growth Factor, sEng= soluble endoglin, sVEGFR-1=soluble vascular endothelial growth factor receptor-1 AST: aspartate aminotransferase

Table VIII

Disposition of the patient after visiting the triage area (hospitalization versus discharge home), rate of preterm delivery and adverse perinatal outcomes according to the previously proposed grading of severity criteria based on plasma MoM concentrations of the PlGF/sVEGFR-1 ratio and the PlGF/sEng ratio.

	PlGF/sVEGFR-1 Ratio (MoM)			PlGF/sEng Ratio (MoM)		
	0.35 Zone 1 (n=15)	0.0351-0.349 Zone 2 (n=11)	0.035 Zone 3 (n=17)	0.30 Zone 1 (n=18)	0.051-0.299 Zone 2 (n=8)	0.05 Zone 3 (n=17)
Home (Column %)	4 (26.7%)	5 (45.5%)	1 (5.9%)	6 (33.3%)	4 (50.0%)	0 (10.5%)
Hospitalized (Column %)	11 (73.3%)	6 (54.5%)	16 (94.1%)	12 (66.7%)	4 (50.0%)	17 (100%)
Risk category	Low	Intermediate	High	Low	Intermediate	High
Number (Row %)	15 (34.9%)	11 (25.6%)	17 (39.5%)	18 (41.9%)	8 (18.6%)	17 (39.5%)
Delivery < 34 weeks	6.7% (1/15)	27.3% (3/11)	94.1% (16/17)	5.6% (1/18)	25.0% (2/8)	100% (17/17)
Delivery within 14 days	6.7% (1/15)	9.1% (1/11)	94.1% (16/17)	5.6% (1/18)	12.5% (1/8)	94.1% (16/17)
Delivery within 7 days	6.7% (1/15)	-- (0/11)	88.2% (15/17)	5.6% (1/18)	12.5% (1/8)	82.4% (14/17)
Maternal morbidity (within 2 weeks)	6.7% (1/15)	0	47.1% (8/17)	5.6% (1/18)	0 (0/8)	47.1% (8/17)
Adverse neonatal outcome (within 2 weeks)	0	0	47.1% (8/17)	0	0	47.1% (8/17)
Composite maternal morbidity and/or adverse neonatal outcome (within 2 weeks)	6.7% (1/15)	0	70.6% (12/17)	6.7% (1/15)	0	70.6% (12/17)

Value expressed as % (n/N)

PlGF= Placental Growth Factor, sEng= soluble endoglin, sVEGFR-1=soluble vascular endothelial growth factor receptor-1